Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

CRF antagonists Dupont.

A Preti1

  • 1Genneruxi Medical Center, Cagliari, Italy. apreti@tin.it

Current Opinion in Investigational Drugs (London, England : 2000)
|January 31, 2002
PubMed
Summary
This summary is machine-generated.

Researchers are investigating corticotropin releasing factor (CRF) ligands as potential treatments for depression and anxiety. Compounds like SV-030 are advancing into preclinical development for these therapeutic applications.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Olfactory dysfunction in patients with type 2 diabetes mellitus.

Rhinology·2024
Same author

Correction to: Cross-cultural adaptation and validation of the SNOT-22 into Italian.

European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery·2022
Same author

Insight into susceptibility genes associated with bipolar disorder: a systematic review.

European review for medical and pharmacological sciences·2021
Same author

Effect of surgery, delivery device and head position on sinus irrigant penetration in a cadaver model.

The Journal of laryngology and otology·2021
Same author

Multiple gene expression profiling suggests epithelial dysfunction in polypoid chronic rhinosinusitis.

Acta otorhinolaryngologica Italica : organo ufficiale della Societa italiana di otorinolaringologia e chirurgia cervico-facciale·2019
Same author

Frontal sinus ablation (Riedel-Mosher’s procedure): indications and role in the endonasal endoscopic era.

Rhinology·2019
Same journal

Reporting disease control rates or clinical benefit rates in early clinical trials of anticancer agents: useful endpoint or hype?

Current opinion in investigational drugs (London, England : 2000)·2011
Same journal

Abating progressive tissue injury and preserving function after CNS trauma: The role of inflammation modulatory therapies.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Teriflunomide, an inhibitor of dihydroorotate dehydrogenase for the potential oral treatment of multiple sclerosis.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Tralokinumab, an anti-IL-13 mAb for the potential treatment of asthma and COPD.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Vedolizumab, a humanized mAb against the α4β7 integrin for the potential treatment of ulcerative colitis and Crohn's disease.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Pitrakinra, a dual IL-4/IL-13 antagonist for the potential treatment of asthma and eczema.

Current opinion in investigational drugs (London, England : 2000)·2010
See all related articles

Area of Science:

  • Neuroscience
  • Pharmacology

Background:

  • Corticotropin-releasing factor (CRF) is implicated in the stress response and has been linked to mood disorders.
  • Developing novel therapeutics for depression and anxiety remains a significant unmet medical need.

Purpose of the Study:

  • To investigate novel corticotropin releasing factor (CRF) ligands for potential antidepressant and anxiolytic properties.
  • To advance specific CRF ligand analogs, such as SV-030, into preclinical development.

Main Methods:

  • Collaborative research involving DuPont, Neurocrine Biosciences, and Cephalon.
  • Focus on the synthesis and evaluation of CRF ligand compounds.
  • Preclinical development of promising analogs.

Main Results:

Related Experiment Videos

  • Identification of CRF ligands with potential therapeutic applications.
  • SV-030 and related analogs are progressing to preclinical stages.

Conclusions:

  • CRF ligands represent a promising class of compounds for treating depression and anxiety.
  • Continued preclinical development is warranted for compounds like SV-030.